Reproductive endocrinology

Abaloparatide and pelvic fracture healing: a phase 2 randomized placebo-controlled trial

Osteoporos IntPublished Randomised controlled trial

Authors' conclusion

In this small study, there was no significant difference in CT radiologic healing, physical performance, or change in pain with ABL vs. placebo in patients with acute pelvic fracture.

Study context

Population
Postmenopausal women and men ≥ 50 years old, enrolled within 4 weeks of pelvic fracture; mean age 82, 93% female
Participants
48 women
Comparison
Abaloparatide vs placebo
Primary endpoint
Fracture healing: CT cortical bridging score on a 5-point scale, assessed by two radiologists
Follow-up
3 months
Methodological detailsphase 2, blinded, placebo-controlled
  • Phase 2
  • Blinded
  • Placebo-controlled

Primary result

As reported in the abstract

CT bridging score distribution
  • No significant difference in bridging score distribution with abaloparatide (ABL) vs placebo (PBO)
  • ABL vs PBO: P = 0.15

Further findings

OutcomeABLPBORR (95% CI)
Healed patients (3 or 4 cortices bridged) · 3 months39%64%0.61 (0.33–1.12)
Healed individual fractures (n = 81) · 3 months47%53%0.88 (0.55–1.40)
Bridging scores, individual fractures (n = 81) · 3 months
P = 0.13
Numeric Rating Scale (NRS) pain score
P < 0.05
  • NRS pain score: baseline; least square means controlling for age, sacral, and displaced fracture

Bridging scores, individual fractures (n = 81) · 3 months

Similar bridging scores with ABL and PBO

NRS pain score

NRS pain higher with PBO than ABL at baseline; no further group differences in change in pain score

Short Physical Performance Battery (SPPB) and TUG

SPPB and TUG scores improved over time in both groups without group differences

Original publication

Abaloparatide and pelvic fracture healing: a phase 2 randomized placebo-controlled trial. Osteoporos Int. Published 20 August 2026. doi:10.1007/s00198-026-08176-2

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.